Stoke Therapeutics stock
STOKNASDAQStoke Therapeutics, Inc., HealthcareISIN US86150R1077
39Score 39 out of 100, Weak
Price and trend
58 / 100
Price history
+4.3% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 15% below it.
Since July 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 32% below its 52-week high. Largest decline in 7 years: 95% (January 2021 to October 2023).
Chart figures for advanced users
- SMA 50$26.52
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$30.81
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.50
- The lowest closing price of the last twelve months.
- Resistance$38.35
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Stoke Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.71B, is number 139 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $184.42M (up 404.5% year on year) and a loss of $6.89M.
- For fiscal 2026, analysts expect on average revenue of $34.39M (down 81.4%) and adjusted earnings per share of −$3.91.
Show more
- MEQIRI Score 39 out of 100 (Weak): rank 572 of 714 in Healthcare, median 53.
- Our model puts fair value at $19.49, with the price 42% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $319.19M, financial debt $0.Stability 56
Weaknesses
- DilutionShare count up 77% since 2020.Capital allocation 18
- Loss-makingLoss of $243.2M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$215.72M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $13.92 and expensive above $32.48 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 9.2%. At 10.2% the fair value would be $16.34, at 8.2% it would be $24.08.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 5.9% on the same quarter a year earlier. Revenue turned from negative at the start of the period to positive ($184.42M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 100%, operating −11%, net −4%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 15 Mar 2027in 123 days
- Last reported
- 29 Oct 2026EPS reported −$1.08 (expected −$0.93)below expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 11.1% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$3.91−7.2%
- Revenue
- $34.39M+7.4%
- Earnings per share
- −$3.99−11.1%
- Revenue
- $47.55M+6.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +9.7%No financial guidance; the US NDA submission is expected in the second half of next year and cash is expected to fund operations through a potential US launch.
“Along with the reimbursement we received from Biogen for zorevunersen-related expenses and a potential development milestone payment, we expect our cash position to fund our operations through a potential U.S. launch in early 2028.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $1.59M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ticho BarrySale
2 Nov 2026, CHIEF MEDICAL OFFICER
- Shares
- 7,195
- Price
- $26.39
- Value
- $189,912
- Allan JonathanSale
2 Oct 2026, GENERAL COUNSEL & CORP Secretary
- Shares
- 627
- Price
- $26.33
- Value
- $16,509
- Ticho BarrySale
1 Oct 2026, CHIEF MEDICAL OFFICER
- Shares
- 1,051
- Price
- $26.16
- Value
- $27,494
Show 8 more
- Ticho BarrySale
1 Sept 2026, CHIEF MEDICAL OFFICER
- Shares
- 5,545
- Price
- $30.67
- Value
- $170,061
- Ticho BarrySale
18 Aug 2026, CHIEF MEDICAL OFFICER
- Shares
- 4,767
- Price
- $32.03
- Value
- $152,690
- Kaye Edward M. MDSale
18 Aug 2026, Board
- Shares
- 12,567
- Price
- $32.03
- Value
- $402,528
- Allan JonathanSale
18 Aug 2026, GENERAL COUNSEL & CORP Secretary
- Shares
- 2,861
- Price
- $32.03
- Value
- $91,639
- Ticho BarrySale
3 Aug 2026, CHIEF MEDICAL OFFICER
- Shares
- 7,176
- Price
- $29.04
- Value
- $208,385
- Ticho BarrySale
1 Jul 2026, CHIEF MEDICAL OFFICER
- Shares
- 7,228
- Price
- $32.66
- Value
- $236,068
- Allan JonathanSale
16 Jun 2026, GENERAL COUNSEL & CORP Secretary
- Shares
- 1,457
- Price
- $29.95
- Value
- $43,637
- Ticho BarrySale
1 Jun 2026, CHIEF MEDICAL OFFICER
- Shares
- 1,795
- Price
- $30.58
- Value
- $54,891
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Stoke Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 39
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Zenas BioPharmaZBIO $1.95B38
- Fortrea HoldingsFTRE $1.93B41
- Kailera TherapeuticsKLRA $1.87B41
- Hemab Therapeutics HoldingsCOAG $1.84B47
- Sarepta TherapeuticsSRPT $1.79B40
- Nurix TherapeuticsNRIX $1.78B69
- MesoblastMESO $1.77B39
- AbsciABSI $1.74B40
ETFs that hold Stoke Therapeutics
Held by 14 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.90% | 0.50% | €127.06M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.16% | 0.40% | €1.49B |
| iShares Ageing Population UCITS ETF2B77 | 0.15% | 0.40% | €807M |
Show 5 more
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.11% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.08% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.05% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Aug 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.